• Connect with us
  • Information
    • About Us
    • Contact Us
    • Careers
    • Partnerships
    • Advertise With Us
    • Authors
    • Browse Topics
    • Events
    • Disclaimer
    • Privacy Policy
  • NORTH AMERICA EDITION
    Australia
    North America
    World
Login
Investing News NetworkYour trusted source for investing success
  • NORTH AMERICA EDITION
    North America
    Australia
    World
  • My INN
Videos
Companies
Press Releases
Private Placements
SUBSCRIBE
  • Reports & Guides
    • Market Outlook Reports
    • Investing Guides
  • Button
Resource
  • Precious Metals
  • Battery Metals
  • Base Metals
  • Energy
  • Critical Minerals
Tech
Life Science
Pharmaceutical Market
Pharmaceutical News
Pharmaceutical Stocks
  • Pharmaceutical Market
  • Pharmaceutical News
  • Pharmaceutical Stocks
pharmaceutical investing

Merus Labs to be Acquired by Norgine

Bryan Mc Govern
May. 12, 2017 08:53AM PST
Pharmaceutical Investing

Merus Labs International Norgine collectively announced a definitive agreement where Norgine will acquire of all Merus’ common shares.

Merus Labs International (TSX:MSL, NASDAQ:MSLI) Norgine collectively announced a definitive agreement where Norgine will acquire of all Merus’ common shares.

As quoted in the press release:
Norgine will acquire all of the issued and outstanding common shares of Merus for $1.65 per share in cash including the assumption of all debt obligations, for a total enterprise value of approximately $342 million (the “Arrangement“). The transaction will be financed through a combination of available cash and new credit facilities that Norgine has secured prior to executing the Arrangement. The transaction price of $1.65 per share represents a premium of 63.4% to the closing price of $1.01 on the TSX on May 10, 2017 and a premium of 55.1% over the 30-day volume weighted average price of $1.06 on the TSX.
Norgine is a leading European specialist pharmaceutical company with a direct commercial presence in all major European markets. In 2016, Norgine’s total sales revenue was €295 million. It employs over 1,000 people across its commercial, development and manufacturing operations and manages all aspects of product development, production, marketing, sales and supply.
Michael Cloutier, Chairman of Merus, commented:
“After a comprehensive review of strategic alternatives, and consultation with the Company’s financial and legal advisors and the Special Committee of Independent Directors, our Board has unanimously concluded that this transaction is in the best interests of the Company and our stakeholders. We are pleased that this transaction appropriately recognizes the value of Merus’ stable legacy product portfolio and strong cash flow.”
Peter Stein, Chairman and Chief Executive Officer of Norgine, commented:
“Our acquisition of Merus will strengthen our position as the ‘go-to’ European specialist pharma company. The Merus team has built a strong platform of established products. We look forward to working closely with the Merus team to efficiently complete this transaction and welcoming them to Norgine.”

Click here to read the full press release.

Source: www.newswire.ca

merus labs review of strategic alternatives pharmaceutical investing
The Conversation (0)

Go Deeper

AI Powered
A floating DNA double helix above a hand with a blue background.

Top 4 NASDAQ Genetics Stocks (Updated January 2026)

Microscopic view of stem cells.

Stem Cell Stocks: 10 Biggest NASDAQ Companies in 2025

Latest News

Outlook Reports

Resource
  • Precious Metals
    • Gold
    • Silver
  • Battery Metals
    • Lithium
    • Cobalt
    • Graphite
    • Electric Vehicles
  • Agriculture
  • Base Metals
    • Copper
    • Nickel
    • Zinc
  • Critical Metals
    • Rare Earths
  • Energy
    • Uranium
    • Oil and Gas
Tech
    • Artificial Intelligence
    • Cybersecurity
    • Robotics
    • Crypto
    • Cleantech
Life Science
    • Biotech
    • Cannabis
    • Pharmaceuticals

Featured Pharmaceutical Investing Stocks

InMed Pharmaceuticals

InMed Pharmaceuticals (INM)
INM

Cardiol Therapeutics

Cardiol Therapeutics (CRDL:CC)
CRDL:CC

Principal Technologies

Principal Technologies (PTEC:CC)
PTEC:CC
More featured stocks

Browse Companies

Resource
  • Precious Metals
  • Battery Metals
  • Energy
  • Base Metals
  • Critical Metals
Tech
Life Science
MARKETS
COMMODITIES
CURRENCIES